patients with an allocation ratio of 2 patients into the control arm (arm A) to 1 patient into one of the 9 experimental arms, of which 6 arms are no longer recruiting after inclusion of more than 7,000 patients. Currently, patients are randomized into one of the remaining 3 arms (arm A, H and J), study completion date for final data collection for primary outcome measure is estimated for September 2017.
Celecoxib (arm D) had shown antiproliferative effect against prostate cancer in vitro and has been evaluated as part of a phase II trial within the STAMPEDE trial. All other study arms are planned as a phase III trial. The primary outcome measure is overall survival (OS) with a targeted relative 25% OS improvement. Secondary study end points are failure-free survival, toxicity, quality of life, skeletal-related events, and cost effectiveness of the different treatments.
Description
This UK-led randomized, open-label trial has been initiated by the Medical Research Council and started recruitment in October 2005. Its large-scale multiarm, multistage, multicenter design is thought to compare the standard of care in hormone-naïve prostate cancers, which is androgen deprivation therapy (ADT), to ADT in combination with 1 or 2 different systemic and / or local treatments, i.e. chemotherapy, bisphosphonates, androgen receptor signaling inhibitors, or radiotherapy. Patients included will have either newly diagnosed localized high-risk, node-positive or metastatic prostate cancers, as well as relapsed disease after previous radical prostatectomy or radiotherapy.
In this largest randomized trial in prostate cancer conducted to date, a total of 10 different study arms are planned to enroll 8,100 Patients with significant cardiovascular disease such that, in the investigator's opinion, the patient is unfit for any of the study treatments. This might include: Severe/unstable angina, myocardial infarction less than 6 months prior to randomization, arterial thrombotic events less than 6 months prior to randomization, clinically significant cardiac failure requiring treatment (NYHA II-IV), cerebrovascular disease (e.g. stroke or transient ischaemic episode) less than 2 years prior to randomization, patients with uncontrolled hypertension defined as systolic BP greater or equal than 160 mmHg or diastolic BP greater or equal than 95 mmHg.
X. Patients receiving treatment with drugs known to induce CYP3A4 (including phenytoin, carbamazepine, Phenobarbital)
XI. Prior exposure to abiraterone XII. Prior exposure to enzalutamide XIII. Prior chemotherapy for prostate cancer XIV. Prior therapy with zoledronic acid or other bisphosphonates other than treatment for hypercalcaemia or low bone density XV. Prior exposure to policy of long-term hormone therapy before randomisation (unless as described in section 4.4.2) XVI. History of seizure including any febrile seizure, loss of consciousness, or transient ischaemic attack within 12 months of randomisation or any condition that may pre-dispose to seizure (e.g., prior stroke, brain arteriovenous malformation, head trauma with loss of consciousness requiring hospitalization) XVII. Unexplained history of loss of consciousness within 12 months of randomisation XVIII. Operation of heavy machinery during treatment
Selection criteria for comparison of research (m1) RT for metastatic disease
All patients meeting criteria in section 4.1 and 4.2 are eligible for the trial, but not all can be allocated to the research (M1) radiotherapy arm. The selection criteria for this 'RT to the prostate' comparison are: • Newly-diagnosed prostate cancer • Demonstrable M1 disease • No contraindication to radiotherapy e.g. no previous pelvic radiotherapy and no history of inflammatory bowel disease • No previous radical prostatectomy Any patients meeting these criteria will have a chance to be allocated to arm H.
Expert Commentary
cantly improved FFS for both metastatic (HR 0.62) and nonmetastatic patients (HR 0.57), while OS was only significantly improved in M1-disease (HR 0.73) (as it was reported by the CHAARTED trial). Adding zoledronic acid to hormone-sensitive disease did not impact FFS or OS, whereas addition of zoledronic acid to ADT + D improved survival but without a substantial benefit over ADT + D [10] . Follow-up of both the GETUG 12 and the STAMPEDE ADT + D study arms is yet insufficient for final estimation of the OS benefit. At last, the phase III RTOG 0521 trial reported a significant improvement of 4-year OS from 89 to 93% in high-risk localized disease by the addition of adjuvant docetaxel following ADT + RT [11] .
The first analyses of the UK-led STAMPEDE trial, together with smaller phase III trials, yield essential data to substantially improve treatment and outcome of patients with hormone-naïve non-metastatic high-risk and metastatic prostate cancer. Addition of docetaxel should be considered in men with metastatic disease eligible for combined treatment, and even for selected men with high-risk non-metastatic disease, where at least FFS can be improved. The early use of zoledronic acid instead did not add any benefit, which is why bisphosphonates are only recommended for castration-resistant metastatic patients. In the future, STAMPEDE will also elucidate the potential of the early use of novel anti-androgenic treatment with abiraterone acetate alone (arm G; already closed) and together with enzalutamide (arm J), which to date have shown to be efficacious in castration-resistant metastatic disease before and after application of docetaxel, and for newly metastatic patients the combined application of ADT + radiotherapy + docetaxel (arm H). Moreover, the multistage, multiarm design appears feasible and efficient to answer complex clinical questions.
Summing up, the STAMPEDE trial has already reported first data of paramount importance, which will impact the treatment of hormone-senstitive high-risk localized and metastatic prostate cancer. Longer follow-up and analyses of the remaining study arms, particularly regarding the early use of the new anti-androgenic agents abiraterone acetate and enzalutamide holds the promise to answer highly relevant questions to substantially improve the standard of care for hormone-naïve prostate cancer patients.
Prof. Dr. Carsten Bokemeyer
Dr. Christoph Oing
Why this Trial Is Important to Us
Prostate cancer is the most common malignancy and a leading cause of cancer deaths in men [1] . The growth-promoting properties of androgens on prostate cancer have been identified already in 1941, when bilateral orchiectomy led to significant shrinkage of prostate cancer metastases [2] . Since then, androgen deprivation therapy (ADT) has been standard of care for highrisk non-metastatic and also metastatic hormone-sensitive prostate cancer. Despite the generally good response to ADT, ADT alone is no curative treatment for most of the patients, but ADT in combination with radiotherapy (RT) has improved overall survival (OS) by 30% and a reduction of cancer-specific mortality by 54% in localized intermediate risk (N0M0) disease [3] . In locally advanced prostate cancer the addition of ADT + RT also beneficially impacted OS over ADT alone (hazard ratio (HR) 0.70) [4] . A post-hoc analysis of 721 patients with newly diagnosed M0 disease included into the STAMPEDE trial confirmed the beneficial use of ADT + RT for both N0M0 patients (HR 0.33), and for the first time for N+M0 disease (HR 0.48) regarding failure-free survival (FFS) [5] . Moreover, a first interim analysis of the STAMPEDE trial did not show any survival benefit by adding the cyclooxygenase-inhibitor celecoxib to ADT (arm D) over ADT alone (control arm A) in newly diagnosed prostate cancer [6] .
Until recently, docetaxel-based conventional chemotherapy was only offered to patients suffering from castration-resistant (after failure of ADT) locally advanced and / or metastatic prostate cancer. The GETUG-AFU 15 trial was the first randomized trial to favor the early use of docetaxel in combination with ADT (ADT + D) in hormone-naïve metastatic prostate cancer yielding a significantly improved radiographic (HR 0.75) and biochemical progression-free survival (HR 0.73), but the trial failed to show an OS benefit by ADT + D as the primary endpoint [7] . Beyond that, the randomized CHAARTED trial reported a significant 13-month OS improvement by ADT + D versus ADT in hormonenaïve metastatic prostate cancer (47.6 vs. 44.0 months; p < 0.001) [8] . The randomized phase III GETUG 12 trial was the first trial to report a beneficial impact of ADT + D in high-risk non-meta
